Tamoxifen- and Placebo-induced Symptoms Yield Similar Adherence Rates to Breast Cancer Prophylactics

Share this content:
The treatment arms had similar rates of non-adherence, suggesting that patients may misattribute naturally occurring symptoms to preventative therapy.
The treatment arms had similar rates of non-adherence, suggesting that patients may misattribute naturally occurring symptoms to preventative therapy.

Women at increased risk of breast cancer taking tamoxifen prophylactically were more likely to be non-adherent if they experienced adverse effects in the first 6 months of therapy, according to a study published in the Journal of Clinical Oncology.1

Patients see at least a 30% reduction in cancer incidence using preventative therapy, yet only 16% of women start once offered. A significant challenge to initiation and adherence is patient concern with adverse effects. In this study, authors investigated the effect of adverse events on long-term adherence.

The International Breast Cancer Invention Study (IBIS-I) was a randomized controlled trial that enrolled pre- and post-menopausal women deemed to be at increased risk of breast cancer. Patients were assigned 1:1 to receive tamoxifen or placebo for 5 years.

Significant differences in rates of adherence occurred after 12 months, and were most prominent at 54 months. The initial 12 to 18 months had the highest rates of discontinuation but decreased afterwards.

Patients experiencing nausea/vomiting were the most likely to be non-adherent — tamoxifen (odds ratio [OR], 0.57; 95% CI: 0.37-0.86; P = .007) and placebo (OR, 0.58; 95% CI: 0.37-0.93; P = .023) — in both study arms.

Gynecologic symptoms were significant only in the tamoxifen arm (OR, 0.77; 95% CI, 0.62-0.97; P = .024).

The overall rate of adherence for at least 4.5 years was about 70% (tamoxifen: 65.2% vs placebo: 74.0%; P < .001).

The treatment arms had similar rates of non-adherence, suggesting that patients may misattribute naturally occurring symptoms to preventative therapy.

RELATED: Tamoxifen or Exemestane With Ovarian Function Suppression Prolongs Breast Cancer-free Interval

The study authors concluded that “intervention strategies are needed to promote adherence, as well as to effectively communicate the harms and benefits of preventative therapy to participants.”

Reference

  1. Smith SG, Sestak I, Howell A, Forbes J, Cuzick J. Participant-reported symptoms and their effect on long-term adherence in the international breast cancer intervention study I (IBIS I). J Clin Oncol. 2017 Jun 29. doi: 10.1200/JCO.2016.71.7439 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters